- Home
- NMG vs AGMB Comparison
NMG vs AGMB Comparison
Compare NMG & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NMG | AGMB |
|---|---|---|
| Founded | 2011 | 2017 |
| Country | Canada | Belgium |
| Employees | N/A | 62 |
| Industry | Other Metals and Minerals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.9M | 562.4M |
| IPO Year | 2015 | N/A |
Fundamental Metrics
Financial Performance| Metric | NMG | AGMB |
|---|---|---|
| Price | $1.27 | $12.55 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 3 |
| Target Price | $5.75 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 581.0K | 89.8K |
| Earning Date | 05-13-2026 | 04-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $17.86 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.28 | $8.75 |
| 52 Week High | $6.06 | $17.82 |
Technical Indicators
Market Signals| Indicator | NMG | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 29.29 | 51.94 |
| Support Level | N/A | $9.54 |
| Resistance Level | $1.67 | $14.19 |
| Average True Range (ATR) | 0.09 | 1.01 |
| MACD | -0.02 | -0.09 |
| Stochastic Oscillator | 1.43 | 49.91 |
Price Performance
Historical ComparisonAbout NMG Nouveau Monde Graphite Inc.
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
About AGMB AgomAb Therapeutics NV American Depositary Shares
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.